Konda A, Nodai A, Soma M, Koga Y, Yoshida H, Toda T, Hayakawa T, Inotsume N
Department of Pharmacy, Tenshi Hospital, Sapporo, Japan.
Eur J Clin Pharmacol. 2008 Apr;64(4):399-404. doi: 10.1007/s00228-007-0423-0. Epub 2007 Dec 18.
To establish a rational ritodrine therapy in relation to serum ritodrine concentration, we examined 14 twin pregnancy patients and determined their pharmacokinetic data.
We measured serum concentrations of ritodrine in twin pregnancy patients using high-performance liquid chromatography (HPLC).
The twin pregnancy patients all exhibited linear ritodrine pharmacokinetic profiles. There was a statistically significant but slight negative correlation between gestation period and ritodrine clearance (y=-0.038x+2.75, r=0.349, p<0.001) among all patients. However, when analyzed on an individual basis, there was a high correlation found in three of the 14 patients.
Due to a decrease in total body clearance in three of the 14 patients, overall serum concentration of ritodrine increased at the end of the pregnancies. To further characterize ritodrine kinetics, additional studies are needed to determine an effective and safe therapy for ritodrine use in twin pregnancy patients.
为了建立与利托君血清浓度相关的合理治疗方案,我们对14例双胎妊娠患者进行了研究,并测定了他们的药代动力学数据。
我们使用高效液相色谱法(HPLC)测定双胎妊娠患者血清中的利托君浓度。
双胎妊娠患者均呈现线性的利托君药代动力学特征。在所有患者中,妊娠期与利托君清除率之间存在统计学显著但微弱的负相关(y = -0.038x + 2.75,r = 0.349,p < 0.001)。然而,在个体分析时,14例患者中有3例呈现高度相关性。
由于14例患者中有3例全身清除率下降,妊娠末期利托君的总体血清浓度升高。为了进一步明确利托君的动力学特征,需要进行更多研究以确定双胎妊娠患者使用利托君的有效且安全的治疗方案。